IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1. For patients with Non Small Cell Lung Cancer (NSCLC):
• •a. Known actionable mutation or rearrangement (including but not limited to the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) gene rearrangements, ROS-1 alterations or BRAF mutations)
• •2. For patient with Hepatocellular carcinoma (HCC):
• •1. Hepatic encephalopathy in the past 12 months.
• •2. Ascites that requires repeated paracentesis in the past 2 months.
• •3. Main portal vein thrombosis.
• •4. Active or prior history of gastrointestinal bleeding in the past 12 months.
• •5. Prior hepatic transplantation.
• •3. Patients with known spinal cord compression.
• •4. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.